SLSSELLAS Life Sciences Group, Inc.vs its industry peers
A metric-by-metric comparison of SELLAS Life Sciences Group, Inc. against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SLSEsta | $2.0B#5 | — | 14.2x#3 | — | -100.0%#4 | 13.0%#2 | — | -19.5%#3 | — | — | 406.5%#2 | — |
| MRNA | $88.5B#1 | — | 13.1x#2 | 45.5x#2 | -39.9%#2 | 20.8%#1 | -158.1%#2 | -41.7%#4 | -54.6%#2 | — | 687.2%#1 | — |
| RVMD | $41.0B#3 | — | 15.7x#4 | — | — | -88.5%#4 | — | -43.4%#5 | — | — | 225.2%#3 | — |
| DNTH | $4.6B#4 | — | 3.9x#1 | 2264.8x#3 | -67.3%#3 | -91.1%#5 | -8739.3%#3 | -13.9%#2 | — | — | — | — |
| NTRA | $59.7B#2 | — | 32.8x#5 | 25.9x#1 | 35.9%#1 | -9.3%#3 | -13.4%#1 | -11.4%#1 | -18.0%#1 | — | — | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-11-01.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice